Moderna (NASDAQ:MRNA) Price Target Lowered to $111.00 at Barclays

Moderna (NASDAQ:MRNA) had its target price trimmed by Barclays from $125.00 to $111.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

MRNA has been the subject of several other reports. Piper Sandler decreased their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Sanford C. Bernstein started coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Jefferies Financial Group lowered their target price on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Finally, UBS Group cut their price target on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $93.18.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $42.75 on Friday. Moderna has a 12-month low of $42.25 and a 12-month high of $170.47. The company has a market cap of $16.43 billion, a PE ratio of -7.35 and a beta of 1.69. The stock has a 50 day simple moving average of $61.85 and a 200-day simple moving average of $99.09. The company has a current ratio of 4.39, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the firm posted ($1.39) EPS. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities research analysts forecast that Moderna will post -9.89 EPS for the current year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,930 shares of company stock valued at $217,170 over the last quarter. Company insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new position in Moderna in the second quarter worth approximately $26,000. Cedar Wealth Management LLC increased its stake in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Family Firm Inc. bought a new position in shares of Moderna during the 2nd quarter valued at $33,000. Bank & Trust Co acquired a new stake in shares of Moderna in the 2nd quarter valued at $36,000. Finally, Hanseatic Management Services Inc. bought a new stake in Moderna in the second quarter worth $48,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.